Vivek Gowda
Vivek Gowda brings over a decade of experience at the forefront of gene editing, with a career spanning Harvard Medical School, Boston University School of Medicine, and CRISPR Therapeutics. At CRISPR Therapeutics, he spent more than seven years leading R&D efforts in in vivo editing and CRISPR-based therapeutic platform development. His work helped advance programs from discovery to CTA/IND, including contributions to the first FDA-approved gene editing therapy.
Vivek has authored multiple regulatory reports supporting genome-editing filings and serves as an advisor on multimillion-dollar biotech investments. His scientific background in systems and cell biology, molecular pharmacology, and translational research underscores his deep commitment to therapeutic innovation.